Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Lymphoid 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 12Leukemia, Myeloid, Acute 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Mantle-Cell 6Leukemia, Lymphocytic, Chronic, B-Cell 6Congenital Abnormalities 6Leukemia, Myelomonocytic, Acute 5Leukemia, Monocytic, Acute 5Leukemia, Erythroblastic, Acute 5Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Lymphoma 4Leukemia, Megakaryoblastic, Acute 4Waldenstrom Macroglobulinemia 3Prostatic Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma, B-Cell, Marginal Zone 3Burkitt Lymphoma 3Sarcoma 2Pancreatic Neoplasms 2Neoplasms 2Multiple Myeloma 2Melanoma 2Lymphoma, Large-Cell, Immunoblastic 2Breast Neoplasms 2Blast Crisis 2Wilms Tumor 1Tumor Lysis Syndrome 1Thromboembolism 1Thrombocytopenia 1

Interventions

Dexamethasone 363Bortezomib 232Lenalidomide 202Cyclophosphamide 174Melphalan 154Calcium Dobesilate 107Peripheral Blood Stem Cell Transplantation 92fludarabine phosphate 84Thalidomide 81Filgrastim 71carfilzomib 68pomalidomide 66Granulocyte Colony-Stimulating Factor 60Mycophenolic Acid 59Busulfan 57daratumumab 55Whole-Body Irradiation 54Tacrolimus 51ixazomib 50Prednisone 50Cyclosporine 49fludarabine 46Antilymphocyte Serum 35Etoposide 30dexamethasone acetate 29Methotrexate 29plerixafor 27Radiotherapy 26Doxorubicin 26dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Multiple Myeloma × alvocidib × Clear all
NCT00082784 2014-12-23

Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

National Cancer Institute (NCI)

Phase 1 Completed
93 enrolled
LymphoidPlasma cell

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00047203 2013-01-16

Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
35 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡